항생제 내성 시장 분석 및 예측(-2035년) : 유형, 제품, 서비스, 기술, 용도, 최종 사용자, 프로세스, 구성 요소, 디바이스, 솔루션

Antibiotic Resistance Market is anticipated to expand from $10.9 billion in 2024 to $21.8 billion by 2034, growing at a CAGR of approximately 8.2%. The Antibiotic Resistance Market encompasses the development and distribution of diagnostics, therapeutics, and preventive measures addressing bacterial resistance to antibiotics. This sector is driven by the urgent need to combat multidrug-resistant strains and ensure effective treatments. Key trends include investments in novel antibiotics, rapid diagnostic tools, and global stewardship programs. Rising healthcare awareness and regulatory support further propel market growth, offering substantial opportunities for innovation and collaboration in addressing this critical public health challenge.

The Antibiotic Resistance Market is experiencing robust growth, fueled by the urgent need for novel treatments and diagnostic tools. Within the therapeutic segment, the beta-lactam and beta-lactamase inhibitors sub-segment is the top-performing, driven by its effectiveness against resistant strains. Glycopeptides emerge as the second highest-performing sub-segment, offering alternatives for multi-drug resistant infections. Diagnostic tools are gaining prominence, with rapid diagnostics leading the charge, enabling timely identification of resistant pathogens. Next-generation sequencing (NGS) technologies follow closely, providing comprehensive resistance profiling. The market is further bolstered by increasing investments in research and development, aimed at discovering new antibiotics and resistance breakers. Public-private partnerships are enhancing innovation, while regulatory support accelerates approval processes. The growing emphasis on antimicrobial stewardship programs underscores the need for sustainable antibiotic use, creating opportunities for companies offering stewardship solutions. As the threat of antibiotic resistance intensifies, strategic collaborations and innovative solutions will be pivotal in shaping the market's future trajectory.

The Antibiotic Resistance Market is witnessing a dynamic shift in market share, pricing, and new product launches. Key industry players are innovating to address the growing resistance challenges, resulting in competitive pricing strategies and cutting-edge product offerings. The focus is on developing broad-spectrum antibiotics and personalized medicine approaches. This market evolution is driven by increasing healthcare demands and a critical need for effective treatments. Competition benchmarking reveals a landscape dominated by a few major pharmaceutical companies, with emerging biotech firms gaining traction. Regulatory influences, particularly in North America and Europe, are shaping market dynamics by enforcing stringent approval processes and incentivizing research. These regulations drive innovation while ensuring safety and efficacy. The market is characterized by strategic partnerships and mergers, enhancing competitive positioning. The global demand for effective antibiotic solutions continues to rise, presenting lucrative opportunities for stakeholders committed to combating antibiotic resistance.

Geographical Overview:

The antibiotic resistance market is witnessing varied growth dynamics across regions, with distinct opportunities emerging. North America leads the market, driven by advanced healthcare infrastructure and significant investments in research to combat antibiotic resistance. The region's proactive measures and government initiatives are crucial in addressing this escalating concern. Europe follows with substantial investments in antibiotic stewardship programs and research initiatives. The European Union's stringent regulations and collaborative efforts among member states are fostering a robust market environment. Asia Pacific is a rapidly growing market, propelled by increasing awareness and rising healthcare expenditures. Countries like China and India are at the forefront, investing heavily in healthcare infrastructure and research to tackle antibiotic resistance. Latin America and the Middle East & Africa are emerging as promising regions. In Latin America, countries like Brazil and Mexico are enhancing their healthcare systems, while in the Middle East & Africa, growing investments in healthcare are paving the way for market expansion.

Global tariffs and geopolitical tensions are significantly influencing the Antibiotic Resistance Market. In Japan and South Korea, strategic investments in biotech innovation and domestic pharmaceutical production are intensifying to mitigate import dependencies. China, facing international scrutiny and trade barriers, is bolstering its internal capabilities through robust R&D initiatives. Taiwan, while a pivotal player in pharmaceutical manufacturing, navigates geopolitical challenges by enhancing regional collaborations. The parent market is witnessing substantial growth driven by rising antimicrobial resistance awareness and government initiatives. By 2035, market evolution will hinge on technological advancements and cross-border partnerships. Concurrently, Middle East conflicts exert pressures on global supply chains and energy prices, indirectly affecting production costs and logistics in the pharmaceutical sector, thereby shaping strategic responses in these East Asian economies.

Key Trends and Drivers:

The antibiotic resistance market is experiencing pivotal growth driven by heightened awareness of antimicrobial resistance (AMR) as a global health threat. Key trends include increased research and development investments in novel antibiotics and alternative therapies. Governments and health organizations are prioritizing AMR action plans, fostering collaborations to combat resistance. Advancements in rapid diagnostic technologies are enabling quicker identification of resistant strains, thereby improving treatment outcomes and reducing inappropriate antibiotic use. The market is also witnessing a surge in public-private partnerships aimed at accelerating drug discovery and development. Regulatory frameworks are evolving to incentivize innovation and streamline approval processes for new antimicrobial agents. Opportunities abound in emerging markets where the burden of infectious diseases is high and healthcare infrastructure is expanding. Companies that focus on developing affordable and accessible solutions are well-positioned to capture significant market share. Additionally, the integration of artificial intelligence in drug discovery processes is expected to further revolutionize the market by enhancing the efficiency and effectiveness of new antibiotic development.

Research Scope:

• Estimates and forecasts the overall market size across type, application, and region.
• Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
• Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
• Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
• Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
• Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
• Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

• 1.1 Market Size and Forecast
• 1.2 Market Overview
• 1.3 Market Snapshot
• 1.4 Regional Snapshot
• 1.5 Strategic Recommendations
• 1.6 Analyst Notes

2 Market Highlights

• 2.1 Key Market Highlights by Type
• 2.2 Key Market Highlights by Product
• 2.3 Key Market Highlights by Services
• 2.4 Key Market Highlights by Technology
• 2.5 Key Market Highlights by Application
• 2.6 Key Market Highlights by End User
• 2.7 Key Market Highlights by Process
• 2.8 Key Market Highlights by Component
• 2.9 Key Market Highlights by Device
• 2.10 Key Market Highlights by Solutions

3 Market Dynamics

• 3.1 Macroeconomic Analysis
• 3.2 Market Trends
• 3.3 Market Drivers
• 3.4 Market Opportunities
• 3.5 Market Restraints
• 3.6 CAGR Growth Analysis
• 3.7 Impact Analysis
• 3.8 Emerging Markets
• 3.9 Technology Roadmap
• 3.10 Strategic Frameworks
  • 3.10.1 PORTER's 5 Forces Model
  • 3.10.2 ANSOFF Matrix
  • 3.10.3 4P's Model
  • 3.10.4 PESTEL Analysis

4 Segment Analysis

• 4.1 Market Size & Forecast by Type (2020-2035)
  • 4.1.1 Antibiotics
  • 4.1.2 Antivirals
  • 4.1.3 Antifungals
  • 4.1.4 Antiparasitics
  • 4.1.5 Others
• 4.2 Market Size & Forecast by Product (2020-2035)
  • 4.2.1 Drugs
  • 4.2.2 Diagnostics
  • 4.2.3 Vaccines
  • 4.2.4 Others
• 4.3 Market Size & Forecast by Services (2020-2035)
  • 4.3.1 Consulting
  • 4.3.2 Laboratory Testing
  • 4.3.3 Surveillance
  • 4.3.4 Others
• 4.4 Market Size & Forecast by Technology (2020-2035)
  • 4.4.1 Genomics
  • 4.4.2 Proteomics
  • 4.4.3 Bioinformatics
  • 4.4.4 Nanotechnology
  • 4.4.5 Others
• 4.5 Market Size & Forecast by Application (2020-2035)
  • 4.5.1 Human Medicine
  • 4.5.2 Veterinary Medicine
  • 4.5.3 Agriculture
  • 4.5.4 Others
• 4.6 Market Size & Forecast by End User (2020-2035)
  • 4.6.1 Hospitals
  • 4.6.2 Clinics
  • 4.6.3 Research Institutes
  • 4.6.4 Pharmaceutical Companies
  • 4.6.5 Others
• 4.7 Market Size & Forecast by Process (2020-2035)
  • 4.7.1 Drug Development
  • 4.7.2 Drug Manufacturing
  • 4.7.3 Quality Control
  • 4.7.4 Others
• 4.8 Market Size & Forecast by Component (2020-2035)
  • 4.8.1 Active Pharmaceutical Ingredients
  • 4.8.2 Excipients
  • 4.8.3 Others
• 4.9 Market Size & Forecast by Device (2020-2035)
  • 4.9.1 Laboratory Instruments
  • 4.9.2 Point-of-Care Devices
  • 4.9.3 Others
• 4.10 Market Size & Forecast by Solutions (2020-2035)
  • 4.10.1 Infection Control
  • 4.10.2 Antimicrobial Stewardship
  • 4.10.3 Others

5 Regional Analysis

• 5.1 Global Market Overview
• 5.2 North America Market Size (2020-2035)
  • 5.2.1 United States
    • 5.2.1.1 Type
    • 5.2.1.2 Product
    • 5.2.1.3 Services
    • 5.2.1.4 Technology
    • 5.2.1.5 Application
    • 5.2.1.6 End User
    • 5.2.1.7 Process
    • 5.2.1.8 Component
    • 5.2.1.9 Device
    • 5.2.1.10 Solutions
  • 5.2.2 Canada
    • 5.2.2.1 Type
    • 5.2.2.2 Product
    • 5.2.2.3 Services
    • 5.2.2.4 Technology
    • 5.2.2.5 Application
    • 5.2.2.6 End User
    • 5.2.2.7 Process
    • 5.2.2.8 Component
    • 5.2.2.9 Device
    • 5.2.2.10 Solutions
  • 5.2.3 Mexico
    • 5.2.3.1 Type
    • 5.2.3.2 Product
    • 5.2.3.3 Services
    • 5.2.3.4 Technology
    • 5.2.3.5 Application
    • 5.2.3.6 End User
    • 5.2.3.7 Process
    • 5.2.3.8 Component
    • 5.2.3.9 Device
    • 5.2.3.10 Solutions
• 5.3 Latin America Market Size (2020-2035)
  • 5.3.1 Brazil
    • 5.3.1.1 Type
    • 5.3.1.2 Product
    • 5.3.1.3 Services
    • 5.3.1.4 Technology
    • 5.3.1.5 Application
    • 5.3.1.6 End User
    • 5.3.1.7 Process
    • 5.3.1.8 Component
    • 5.3.1.9 Device
    • 5.3.1.10 Solutions
  • 5.3.2 Argentina
    • 5.3.2.1 Type
    • 5.3.2.2 Product
    • 5.3.2.3 Services
    • 5.3.2.4 Technology
    • 5.3.2.5 Application
    • 5.3.2.6 End User
    • 5.3.2.7 Process
    • 5.3.2.8 Component
    • 5.3.2.9 Device
    • 5.3.2.10 Solutions
  • 5.3.3 Rest of Latin America
    • 5.3.3.1 Type
    • 5.3.3.2 Product
    • 5.3.3.3 Services
    • 5.3.3.4 Technology
    • 5.3.3.5 Application
    • 5.3.3.6 End User
    • 5.3.3.7 Process
    • 5.3.3.8 Component
    • 5.3.3.9 Device
    • 5.3.3.10 Solutions
• 5.4 Asia-Pacific Market Size (2020-2035)
  • 5.4.1 China
    • 5.4.1.1 Type
    • 5.4.1.2 Product
    • 5.4.1.3 Services
    • 5.4.1.4 Technology
    • 5.4.1.5 Application
    • 5.4.1.6 End User
    • 5.4.1.7 Process
    • 5.4.1.8 Component
    • 5.4.1.9 Device
    • 5.4.1.10 Solutions
  • 5.4.2 India
    • 5.4.2.1 Type
    • 5.4.2.2 Product
    • 5.4.2.3 Services
    • 5.4.2.4 Technology
    • 5.4.2.5 Application
    • 5.4.2.6 End User
    • 5.4.2.7 Process
    • 5.4.2.8 Component
    • 5.4.2.9 Device
    • 5.4.2.10 Solutions
  • 5.4.3 South Korea
    • 5.4.3.1 Type
    • 5.4.3.2 Product
    • 5.4.3.3 Services
    • 5.4.3.4 Technology
    • 5.4.3.5 Application
    • 5.4.3.6 End User
    • 5.4.3.7 Process
    • 5.4.3.8 Component
    • 5.4.3.9 Device
    • 5.4.3.10 Solutions
  • 5.4.4 Japan
    • 5.4.4.1 Type
    • 5.4.4.2 Product
    • 5.4.4.3 Services
    • 5.4.4.4 Technology
    • 5.4.4.5 Application
    • 5.4.4.6 End User
    • 5.4.4.7 Process
    • 5.4.4.8 Component
    • 5.4.4.9 Device
    • 5.4.4.10 Solutions
  • 5.4.5 Australia
    • 5.4.5.1 Type
    • 5.4.5.2 Product
    • 5.4.5.3 Services
    • 5.4.5.4 Technology
    • 5.4.5.5 Application
    • 5.4.5.6 End User
    • 5.4.5.7 Process
    • 5.4.5.8 Component
    • 5.4.5.9 Device
    • 5.4.5.10 Solutions
  • 5.4.6 Taiwan
    • 5.4.6.1 Type
    • 5.4.6.2 Product
    • 5.4.6.3 Services
    • 5.4.6.4 Technology
    • 5.4.6.5 Application
    • 5.4.6.6 End User
    • 5.4.6.7 Process
    • 5.4.6.8 Component
    • 5.4.6.9 Device
    • 5.4.6.10 Solutions
  • 5.4.7 Rest of APAC
    • 5.4.7.1 Type
    • 5.4.7.2 Product
    • 5.4.7.3 Services
    • 5.4.7.4 Technology
    • 5.4.7.5 Application
    • 5.4.7.6 End User
    • 5.4.7.7 Process
    • 5.4.7.8 Component
    • 5.4.7.9 Device
    • 5.4.7.10 Solutions
• 5.5 Europe Market Size (2020-2035)
  • 5.5.1 Germany
    • 5.5.1.1 Type
    • 5.5.1.2 Product
    • 5.5.1.3 Services
    • 5.5.1.4 Technology
    • 5.5.1.5 Application
    • 5.5.1.6 End User
    • 5.5.1.7 Process
    • 5.5.1.8 Component
    • 5.5.1.9 Device
    • 5.5.1.10 Solutions
  • 5.5.2 France
    • 5.5.2.1 Type
    • 5.5.2.2 Product
    • 5.5.2.3 Services
    • 5.5.2.4 Technology
    • 5.5.2.5 Application
    • 5.5.2.6 End User
    • 5.5.2.7 Process
    • 5.5.2.8 Component
    • 5.5.2.9 Device
    • 5.5.2.10 Solutions
  • 5.5.3 United Kingdom
    • 5.5.3.1 Type
    • 5.5.3.2 Product
    • 5.5.3.3 Services
    • 5.5.3.4 Technology
    • 5.5.3.5 Application
    • 5.5.3.6 End User
    • 5.5.3.7 Process
    • 5.5.3.8 Component
    • 5.5.3.9 Device
    • 5.5.3.10 Solutions
  • 5.5.4 Spain
    • 5.5.4.1 Type
    • 5.5.4.2 Product
    • 5.5.4.3 Services
    • 5.5.4.4 Technology
    • 5.5.4.5 Application
    • 5.5.4.6 End User
    • 5.5.4.7 Process
    • 5.5.4.8 Component
    • 5.5.4.9 Device
    • 5.5.4.10 Solutions
  • 5.5.5 Italy
    • 5.5.5.1 Type
    • 5.5.5.2 Product
    • 5.5.5.3 Services
    • 5.5.5.4 Technology
    • 5.5.5.5 Application
    • 5.5.5.6 End User
    • 5.5.5.7 Process
    • 5.5.5.8 Component
    • 5.5.5.9 Device
    • 5.5.5.10 Solutions
  • 5.5.6 Rest of Europe
    • 5.5.6.1 Type
    • 5.5.6.2 Product
    • 5.5.6.3 Services
    • 5.5.6.4 Technology
    • 5.5.6.5 Application
    • 5.5.6.6 End User
    • 5.5.6.7 Process
    • 5.5.6.8 Component
    • 5.5.6.9 Device
    • 5.5.6.10 Solutions
• 5.6 Middle East & Africa Market Size (2020-2035)
  • 5.6.1 Saudi Arabia
    • 5.6.1.1 Type
    • 5.6.1.2 Product
    • 5.6.1.3 Services
    • 5.6.1.4 Technology
    • 5.6.1.5 Application
    • 5.6.1.6 End User
    • 5.6.1.7 Process
    • 5.6.1.8 Component
    • 5.6.1.9 Device
    • 5.6.1.10 Solutions
  • 5.6.2 United Arab Emirates
    • 5.6.2.1 Type
    • 5.6.2.2 Product
    • 5.6.2.3 Services
    • 5.6.2.4 Technology
    • 5.6.2.5 Application
    • 5.6.2.6 End User
    • 5.6.2.7 Process
    • 5.6.2.8 Component
    • 5.6.2.9 Device
    • 5.6.2.10 Solutions
  • 5.6.3 South Africa
    • 5.6.3.1 Type
    • 5.6.3.2 Product
    • 5.6.3.3 Services
    • 5.6.3.4 Technology
    • 5.6.3.5 Application
    • 5.6.3.6 End User
    • 5.6.3.7 Process
    • 5.6.3.8 Component
    • 5.6.3.9 Device
    • 5.6.3.10 Solutions
  • 5.6.4 Sub-Saharan Africa
    • 5.6.4.1 Type
    • 5.6.4.2 Product
    • 5.6.4.3 Services
    • 5.6.4.4 Technology
    • 5.6.4.5 Application
    • 5.6.4.6 End User
    • 5.6.4.7 Process
    • 5.6.4.8 Component
    • 5.6.4.9 Device
    • 5.6.4.10 Solutions
  • 5.6.5 Rest of MEA
    • 5.6.5.1 Type
    • 5.6.5.2 Product
    • 5.6.5.3 Services
    • 5.6.5.4 Technology
    • 5.6.5.5 Application
    • 5.6.5.6 End User
    • 5.6.5.7 Process
    • 5.6.5.8 Component
    • 5.6.5.9 Device
    • 5.6.5.10 Solutions

6 Market Strategy

• 6.1 Demand-Supply Gap Analysis
• 6.2 Trade & Logistics Constraints
• 6.3 Price-Cost-Margin Trends
• 6.4 Market Penetration
• 6.5 Consumer Analysis
• 6.6 Regulatory Snapshot

7 Competitive Intelligence

• 7.1 Market Positioning
• 7.2 Market Share
• 7.3 Competition Benchmarking
• 7.4 Top Company Strategies

8 Company Profiles

• 8.1 Melinta Therapeutics
  • 8.1.1 Overview
  • 8.1.2 Product Summary
  • 8.1.3 Financial Performance
  • 8.1.4 SWOT Analysis
• 8.2 Nabriva Therapeutics
  • 8.2.1 Overview
  • 8.2.2 Product Summary
  • 8.2.3 Financial Performance
  • 8.2.4 SWOT Analysis
• 8.3 Paratek Pharmaceuticals
  • 8.3.1 Overview
  • 8.3.2 Product Summary
  • 8.3.3 Financial Performance
  • 8.3.4 SWOT Analysis
• 8.4 Iterum Therapeutics
  • 8.4.1 Overview
  • 8.4.2 Product Summary
  • 8.4.3 Financial Performance
  • 8.4.4 SWOT Analysis
• 8.5 Motif Bio
  • 8.5.1 Overview
  • 8.5.2 Product Summary
  • 8.5.3 Financial Performance
  • 8.5.4 SWOT Analysis
• 8.6 Spero Therapeutics
  • 8.6.1 Overview
  • 8.6.2 Product Summary
  • 8.6.3 Financial Performance
  • 8.6.4 SWOT Analysis
• 8.7 Entasis Therapeutics
  • 8.7.1 Overview
  • 8.7.2 Product Summary
  • 8.7.3 Financial Performance
  • 8.7.4 SWOT Analysis
• 8.8 Achaogen
  • 8.8.1 Overview
  • 8.8.2 Product Summary
  • 8.8.3 Financial Performance
  • 8.8.4 SWOT Analysis
• 8.9 Venatorx Pharmaceuticals
  • 8.9.1 Overview
  • 8.9.2 Product Summary
  • 8.9.3 Financial Performance
  • 8.9.4 SWOT Analysis
• 8.10 Qpex Biopharma
  • 8.10.1 Overview
  • 8.10.2 Product Summary
  • 8.10.3 Financial Performance
  • 8.10.4 SWOT Analysis
• 8.11 Forge Therapeutics
  • 8.11.1 Overview
  • 8.11.2 Product Summary
  • 8.11.3 Financial Performance
  • 8.11.4 SWOT Analysis
• 8.12 Bugworks Research
  • 8.12.1 Overview
  • 8.12.2 Product Summary
  • 8.12.3 Financial Performance
  • 8.12.4 SWOT Analysis
• 8.13 Nosopharm
  • 8.13.1 Overview
  • 8.13.2 Product Summary
  • 8.13.3 Financial Performance
  • 8.13.4 SWOT Analysis
• 8.14 Bioversys
  • 8.14.1 Overview
  • 8.14.2 Product Summary
  • 8.14.3 Financial Performance
  • 8.14.4 SWOT Analysis
• 8.15 Debiopharm
  • 8.15.1 Overview
  • 8.15.2 Product Summary
  • 8.15.3 Financial Performance
  • 8.15.4 SWOT Analysis
• 8.16 Antabio
  • 8.16.1 Overview
  • 8.16.2 Product Summary
  • 8.16.3 Financial Performance
  • 8.16.4 SWOT Analysis
• 8.17 Acurx Pharmaceuticals
  • 8.17.1 Overview
  • 8.17.2 Product Summary
  • 8.17.3 Financial Performance
  • 8.17.4 SWOT Analysis
• 8.18 Aridis Pharmaceuticals
  • 8.18.1 Overview
  • 8.18.2 Product Summary
  • 8.18.3 Financial Performance
  • 8.18.4 SWOT Analysis
• 8.19 Macrolide Pharmaceuticals
  • 8.19.1 Overview
  • 8.19.2 Product Summary
  • 8.19.3 Financial Performance
  • 8.19.4 SWOT Analysis
• 8.20 Allecra Therapeutics
  • 8.20.1 Overview
  • 8.20.2 Product Summary
  • 8.20.3 Financial Performance
  • 8.20.4 SWOT Analysis

9 About Us

• 9.1 About Us
• 9.2 Research Methodology
• 9.3 Research Workflow
• 9.4 Consulting Services
• 9.5 Our Clients
• 9.6 Client Testimonials
• 9.7 Contact Us